OneSource Q2: Revenue Up 37% and EBITDA Up 53% as New Drug-Device Capacity Starts Paying Off
Big drug companies no longer want to make everything themselves. Injectable pens, biologics and complex formulations need specialised plants, spotless quality records and years of regulatory work, so many hands that job to contract manufacturers. Winning that trust is slow, but once a product is approved and running, these relationships tend to last for years. That makes capacity and compliance the real currency of the business.
The Nifty 50 was trading at 22,714.65, down 0.18%. Meanwhile, Sensex also fell 0.26% to 73,411.18 on Tuesday. Meanwhile, Shares of OneSource Specialty Pharma were trading at Rs. 1,587.00, up 13.58 percent from previous close of Rs. 1,397.30. The stock opened at Rs. 1,402.70 and reached an intraday high of Rs. 1,533.50 and low of Rs. 1,384.10. The company currently has a market capitalization of Rs. 18,181 crores.
Also Read: L&T wins major Dhaka Metro Line 1 systems packages worth up to ₹10,000 Cr in partnership with Sumitomo Corporation
What's the News
OneSource Specialty Pharma's September-quarter revenue rose 37% from a year ago and 15% from the previous quarter. EBITDA grew 53%, with margin improving to about 32%, and adjusted profit more than doubled. It was the company's third straight quarter of sequential revenue growth, and the first full quarter with its second cartridge line running commercially.
Management credits new drug-device combination (DDC) capacity, steady execution under master service agreements and 12 product launches across North America, the Middle East and Latin America. The CEO expects new launches and a significant ramp-up in commercial volumes in the second half. The company also reaffirmed its FY28 outlook of $400 million in organic revenue.
Financial & Business Analysis
Looking at the quarterly results of OneSource Specialty Pharma, the company's consolidated revenue from operations increased by 37.39 percent YoY, from Rs. 375.76 crore in Q2 FY26 to Rs. 516.24 crore in Q2 FY27, and increased by 14.97 percent QoQ from Rs. 449.02 crore in Q1 FY27.
In Q2 FY27 OneSource Specialty Pharma, consolidated net profit increased by 820.56 percent YoY, reaching Rs. 52.86 crore compared to Rs. 5.74 crore during the same period last year. As compared to Q1 FY27, the net profit increased by 160.54 percent, from Rs. 20.29 crore. The basic earnings per share stood at Rs. 5.01 as against Rs. 0.92 recorded in the same quarter in the previous year, FY2026.
OneSource sells through four offerings: DDC (which includes GLP-1 pens), biologics, soft gelatin capsules and sterile injectables. Value Research's read of the FY28 plan is that the existing businesses contribute roughly a quarter of the target, with DDC providing almost all the rest, while biologics remains the smallest, earliest-stage piece. The mix is clearly shifting towards DDC, and that is where margins are better.
The company doesn't report a formal order book, but its pipeline tells the story. It signed six new wins this quarter, two of them in biologics, added two new customers to cross 82, and has over 75 active RFPs. With DDC capacity set to triple by FY28, these wins are what will fill the new lines. Approval timing can still swing a quarter, as delayed Canadian approvals showed in Q3 FY26.
Industry Context
Two big therapy areas are pulling demand. HDFC Securities projects the global GLP-1 market growing from about $53 billion to $126 billion, at roughly 19% a year, and biosimilars from about $33 billion to nearly $79 billion, at around 18.8%. Both depend on complex fill-finish and device capacity, which is exactly what OneSource has been building.
India stands to gain from this shift. McKinsey says India could hold 8 to 10% of the global CDMO market by 2033 as buyers diversify supply chains. The near term is less certain, though. Industry reports call 2026 a reset year, with global outsourcing growing at a mid-single-digit rate. In that environment, the winners will be companies that turn pipelines into commercial volumes.
Company Overview
OneSource Specialty Pharma, formerly Stelis Biopharma, is a pure-play specialty pharmaceutical CDMO. It develops and manufactures biologics, drug-device combinations, sterile injectables and oral softgel products. It runs five manufacturing facilities approved by global regulators, has completed 220+ audits and employs over 1,600 professionals.